Further studies are certainly warranted to interrogate this theory and elucidate whether CD69 may be a viable novel target for cancer immunotherapy in OGJ in combination with FLOT or CROSS regimens to prevent tumour immune escape mediated by T cell exhaustion. Here, CD69 is linked to neoplasm.